family with sequence similarity 178 member BGenealiases: []
Q-omics provides the consensus-scored FAM178B profile across patient tissues and cancer cell-line models. FAM178B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FAM178B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FAM178B RNA expression shows 13,351 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, THCA, and GBM as cancer lineages where FAM178B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM178B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM178B survival associations across molecular data types. FAM178B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM178B RNA expression–survival associations across cancer types. High FAM178B expression shows unfavorable associations in KIRP, KICH, LGG and KIRC, but favorable associations in ACC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FAM178B RNA expression.
This table summarizes FAM178B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM178B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM178B shows lower tumor expression in KICH and BLCA and higher tumor expression in THCA, LUAD, HNSC and LIHC. The THCA box plot shows higher FAM178B RNA expression in tumor versus normal tissue (log2 FC = +1.975, t-test p < 0.001).
This table shows molecular features associated with FAM178B in patient tissues and cancer cell lines. In patient samples, FAM178B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM178B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
